Zuranolone Beneficial for Treatment of Postpartum Depression
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, July 31, 2023 -- For women with severe postpartum depression (PPD), zuranolone yields significant improvements in depressive symptoms, according to a study published online July 26 in The American Journal of Psychiatry.
Kristina M. Deligiannidis, M.D., from the Feinstein Institutes for Medical Research at Northwell Health in Manhasset, New York, and colleagues conducted a double-blind phase 3 trial involving women with severe PPD who were randomly assigned to receive zuranolone or placebo for 14 days (98 patients to each). Of the participants, 86.7 percent completed the 45-day study.
The researchers found that compared with placebo, treatment with zuranolone resulted in statistically significant improvement in depressive symptoms at day 15 (least squares mean change from baseline in 17-item Hamilton Depression Rating Scale, −15.6 versus −11.6); at days 3, 28, and 45, significant improvements in depressive symptoms were also reported. At day 15, the Clinical Global Impressions severity score significantly improved with zuranolone versus placebo. Somnolence, dizziness, and sedation were the most common adverse events with zuranolone (≥10 percent). There was no loss of consciousness, withdrawal symptoms, or increased suicidal ideation or behavior reported.
"Standard-of-care antidepressants often must be taken chronically and generally require weeks to months to take effect, leading to substantial morbidity," the authors write. "Therefore, if approved, zuranolone would be the first short-course, rapid-acting, oral treatment for patients with PPD."
Several authors disclosed ties to biopharmaceutical companies, including Sage Therapeutics and Biogen, which manufacture zuranolone and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
American College of Obstetricians and Gynecologists, May 17-19
The annual meeting of the American College of Obstetricians and Gynecologists was held from May 17 to 19 in San Francisco and was attended by more than 4,000 clinicians...
Epidural Analgesia Linked to Decline in Severe Maternal Morbidity
FRIDAY, May 24, 2024 -- Epidural analgesia during labor is associated with a reduction in severe maternal morbidity (SMM), according to a study published online May 22 in The...
Prenatal Exposure to Endocrine-Disrupting Chemicals Affects Child's Metabolic Health
FRIDAY, May 24, 2024 -- Prenatal exposure to endocrine-disrupting chemicals (EDCs) is associated with adverse metabolic health in children, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.